<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTISPORIN-TC - colistin sulfate, neomycin sulfate, thonzonium bromide and hydrocortisone acetate suspension </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>Cortisporin<span class="Sup">®</span>-TC Otic Suspension with Neomycin and <br>Hydrocortisone (colistin sulfate—neomycin sulfate—thonzonium <br>bromide—hydrocortisone acetate otic suspension)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cortisporin<span class="Sup">®</span>-TC Otic Suspension with Neomycin and Hydrocortisone (colistin sulfate—neomycin sulfate—thonzonium bromide—hydrocortisone acetate otic suspension) is a sterile antibacterial and anti-inflammatory aqueous suspension containing in each mL: Colistin base activity, 3 mg (as the sulfate); Neomycin base activity, 3.3 mg (as the sulfate); Hydrocortisone acetate, 10 mg (1%); Thonzonium bromide, </p>
<p>0.5 mg (0.05%); Polysorbate 80, acetic acid, and sodium acetate in a buffered aqueous vehicle. Thimerosal (mercury derivative), 0.002%, is added as a preservative. It is a nonviscous liquid, buffered at pH 5, for instillation into the canal of the external ear or direct application to the affected aural skin. </p>
<p>The structural formulas of colistin sulfate (mixture of Colistin A &amp; B), neomycin sulfate (mixture of neomycin A, B &amp; C), hydrocortisone acetate ((11β)-21-(acetyloxy)-11,17-dihydroxypregn) methyl]-2 pyrimidinylamino] ethyl]-N,N-dimethyl-1-hexadecanaminium, bromide) are represented below: </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-01.jpg"></p>
<p><span class="Italics">Thonzonium Bromide </span></p>
<p> </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-02.jpg"></p>
<p><span class="Italics">Colistin sulfate </span></p>
<p> </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-03.jpg"></p>
<p><span class="Italics">Neomycin A </span></p>
<p> </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-04.jpg"></p>
<p><span class="Italics">Neomycin B Sulfate </span></p>
<p> </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-05.jpg"></p>
<p><span class="Italics">Hydrocortisone Acetate </span></p>
<p> </p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=cortisporin-06.jpg"></p>
<p><span class="Italics">Neomycin C Sulfate </span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Colistin sulfate is a polypeptide antibiotic which penetrates into and disrupts the bacterial cell membrane. Neomycin sulfate is an aminoglycoside antibiotic which inhibits protein synthesis, disrupting the normal cycle of ribosomal function. Hydrocortisone acetate is a corticosteroid hormone which is thought to act by regulating the rate of protein synthesis; it controls <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> and other dermal reactions. Cortiscosteroids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case. </p>
<p>The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle. </p>
<p>Thonzonium bromide is a surface-active agent that promotes tissue contact by dispersion and penetration of the cellular debris and exudate. </p>
<div class="Section" data-sectionCode="49489-8">
<a name="section-2.1"></a><p></p>
<h2>Microbiology</h2>
<p class="First">Together, colistin sulfate and neomycin sulfate have bactericidal activity against most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following microorganisms, both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section. </p>
<p><span class="Bold">Aerobic gram-positive microorganisms: </span></p>
<p><span class="Italics">Staphylococcus aureus. </span></p>
<p><span class="Bold">Aerobic gram-negative microorganisms: </span></p>
<p><span class="Italics">Enterobacter aerogenes<br>Escherichia coli<br>Klebsiella pneumoniae<br>Pseudomonas aeruginosa. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<h3>Susceptibility Tests</h3>
<p class="First">It is not recommended that colistin sulfate or neomycin sulfate be routinely tested and reported by clinical microbiology laboratories.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Cortisporin<span class="Sup">®</span>-TC Otic Suspension is indicated for the treatment of superficial <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">This product is contraindicated in those individuals who have shown <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of its components. </p>
<p>This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span> (e.g., herpes simplex virus or <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> virus). </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Warnings"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Neomycin can induce permanent <span class="product-label-link" type="condition" conceptid="374366" conceptname="Sensorineural hearing loss">sensorineural hearing loss</span> due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days. (See <a href="#PreGen">PRECAUTIONS-General</a>.) Patients being treated with eardrops containing neomycin should be under close clinical observation. Cortisporin<span class="Sup">®</span>-TC Otic Suspension should be used cautiously in any patient with a perforated tympanic membrane. </p>
<p>Neomycin sulfate may cause cutaneous sensitization. A precise incidence of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (primarily <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>) due to topical neomycin is not known. Discontinue promptly if sensitivity or irritation occurs. </p>
<p>When using neomycin-containing products to control <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span> in the chronic dermatoses, such as chronic <span class="product-label-link" type="condition" conceptid="380731" conceptname="Otitis externa">otitis externa</span> or <span class="product-label-link" type="condition" conceptid="4148876" conceptname="Stasis dermatitis">stasis dermatitis</span>, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is ususally a low-grade reddening with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, dry scaling, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="PreGen"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">As with any other antibiotic preparation, prolonged treatment may result in overgrowth of nonsusceptible organisms and fungi. If the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not improved after one week, cultures should be repeated to verify the identity of the organism and to determine whether therapy should be changed. </p>
<p>Treatment should not be continued for longer than ten days. </p>
<p>Allergic cross-reactions may occur which could prevent the use of any or all of the aminoglycoside antibiotics for the treatment of future <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-6.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Avoid contaminating the dropper with material from the ear, fingers, or other source. This caution is necessary if the <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> of the drops is to be preserved. </p>
<p>If sensitization or irritation occurs, discontinue use immediately and contact your physician. </p>
<p><span class="Bold">Do not use in the eyes. </span></p>
<p>If you prefer to warm the medication before using it, do not heat the suspension above body temperature in order to avoid loss of potency. </p>
<p><span class="Bold">SHAKE WELL BEFORE USING.</span></p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="section-6.3"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Systemic effects of excessive levels of hydrocortisone may include a reduction in the number of circulating eosinophils and a decrease in urinary excretion of 17-hydroxycorticosteroids. </p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-6.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term animal carcinogenicity studies have not been performed with colistin or neomycin, or Cortisporin<span class="Sup">®</span>-TC Otic Suspension. An increased incidence of chromosome aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> has been reported following <span class="Italics">in vitro </span>exposure to colistin or neomycin. </p>
<p>Fertility studies have not been performed with neomycin, but reports from the scientific literature suggest that it may decrease spermatogenesis in rats. No adverse effects on fertility were observed in male or female rats given intramuscular doses of colistimethate sodium, the methanesulfonate salt of colistin, up to 20 mg/kg (equivalent to 9.3 mg/kg of colistin base). This is approximately 30 times the clinical daily dose based on body surface area, assuming 100% absorption from the ear; however, significant systemic levels of colistin or neomycin would not be anticipated in humans when Cortisporin<span class="Sup">®</span>-TC Otic Suspension is used as directed. </p>
<p>Long term studies in rodents showed no evidence of carcinogenicity attributable to oral administration of corticosteroids. Mutagenicity studies with hydrocortisone were negative. Studies have not been performed to evaluate the effect on fertility of topical corticosteroids. </p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-6.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-6.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">There are no adequate and well controlled studies of Cortisporin<span class="Sup">®</span>-TC Otic Suspension in pregnant women. It is not known whether Cortisporin<span class="Sup">®</span>-TC Otic Suspension can cause fetal harm when administered to a pregnant woman. </p>
<p>Colistimethate sodium, the methanesulfonate salt of colistin, was not teratogenic in rats or rabbits given intramuscular doses up to 20 mg/kg (equivalent to 9.3 mg/kg of colisitin base, approximately 30 times (rats) or 55 times (rabbits) the clinical daily dose based on body suface area and assuming 100% absorption from the ear). Increased resorptions were observed in rabbits at 20 mg/kg, but not 10 mg/kg (equivalent to 4.15 mg/kg of colistin base). Decreased pup survival at weaning was observed in rats at 20 mg/kg, a maternally toxic dose of colistin, but not 10 mg/kg. Colistin has not been shown to have any adverse effects on the developing embryo or fetus at doses relevant to the amount that will be delivered ototopically at the recommended clinical doses. </p>
<p>Although aminoglycosides can cause <span class="product-label-link" type="condition" conceptid="4318712" conceptname="Congenital deafness">congenital deafness</span> in humans if administered during pregnancy, significant systemic levels of neomycin would not be anticipated when Cortisporin<span class="Sup">®</span>-TC Otic Suspension is used as directed. </p>
<p>Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. </p>
<p>Cortisporin<span class="Sup">®</span>-TC Otic Suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. </p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-6.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Hydrocortisone and colistin sulfate appear in human milk following oral administration of the drugs. Since systemic absorption of these drugs may occur when they are used topically, caution should be exercised when Cortisporin<span class="Sup">®</span>-TC Otic Suspension is used by a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-6.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">See <span class="Bold"><a href="#DA">DOSAGE AND ADMINISTRATION</a></span>. </p>
<p>The safety and effectiveness of Cortisporin<span class="Sup">®</span>-TC Otic Suspension in infants below one year of age have not been established. The efficacy of Cortisporin<span class="Sup">®</span>-TC Otic Suspension in pediatric patients one year or older in the treatment of superficial <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span> of the external auditory canal and for the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of mastoidectomy and fenestration cavities has been demonstrated in a controlled clinical trial.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-6.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Neomycin occasionally causes skin sensitization. </p>
<p><span class="product-label-link" type="condition" conceptid="4236623" conceptname="Ototoxicity">Ototoxicity</span> (see <a href="#Warnings">WARNINGS</a> section) and <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> have also been reported. Adverse reactions have occurred with topical use of antibiotic combinations. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced <span class="product-label-link" type="condition" conceptid="4070025" conceptname="Cutaneous hypersensitivity">allergic skin reactions</span> occurred in two of 2,175 (0.09%) individuals in the general populaton. In another study the incidence was found to be approximately 1%.</p>
<p>The following local adverse events have been reported with topical corticosteroids, especially under occlusive dressings: burning, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, irritation, dryness, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, maceration of the skin, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>. </p>
<p>For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1-800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="DA"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Therapy with this product should be limited to 10 days. (See <a href="#Warnings">WARNINGS</a>.) </p>
<p>The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. </p>
<p>When using the calibrated dropper: </p>
<p>For adults, 5 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For pediatric patients, 4 drops are suggested because of the smaller capacity of the ear canal. </p>
<p>The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. </p>
<p>If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further solution every 4 hours. The wick should be replaced at least once every 24 hours. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Cortisporin<span class="Sup">®</span>-TC Otic Suspension is supplied as: </p>
<p>NDC 54868-0564-0 ............... 10 mL bottle with dropper</p>
<p>Each mL contains: Colistin sulfate equivalent to 3 mg of colistin base activity, Neomycin sulfate equivalent to 3.3 mg neomycin base activity, Hydrocortisone acetate 10 mg (1%), Thonzonium bromide 0.5 mg (0.05%), and Polysorbate 80 in an aqueous vehicle buffered with acetic acid and sodium acetate. Thimerosal (mercury derivative) 0.002% is added as a preservative. </p>
<p>A sterilized dropper-cap assembly for use on the bottle of suspension is included in the package. </p>
<p><span class="Bold">Shake well before using. </span></p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-9.1"></a><p></p>
<p class="First"><span class="Bold">Store at 20°–25°C (68°–77°F).</span></p>
<p><span class="Bold">Rx only. </span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-10"></a><p></p>
<p class="First">Prescribing Information as of July 2009 </p>
<p>Manufactured by: JHP Pharmaceuticals, LLC, Rochester, MI 48307 </p>
<p>3000828C</p>
<br><p><br></p>
<p><span class="Bold">Relabeling of "Additional Barcode" label by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OK       74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 mL Carton</h1>
<p class="First"><span>Cortisporin<span class="Sup">®</span>-TC</span></p>
<p><span class="Italics">(colistin sulfate–neomycin sulfate–<br>thonzonium bromide–hydrocortisone<br>acetate otic suspension)</span></p>
<p><span class="Bold">NOTE –</span> The enclosed dropper has been sterilized. If dropper<br>wrapper is broken or open, <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be guaranteed.</p>
<p><span class="Bold">Rx</span> Only</p>
<p><span class="Bold">STERILE<br>Shake Well Before Using.</span></p>
<p><span class="Bold">10mL bottle with dropper</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=0869fd8d-6dd7-4dc2-b33c-20d72dc47718&amp;name=0564.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTISPORIN-TC 		
					</strong><br><span class="contentTableReg">colistin sulfate, neomycin sulfate, thonzonium bromide, and hydrocortisone acetate suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-0564(NDC:42023-109-01)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">AURICULAR (OTIC)</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>COLISTIN SULFATE</strong> (COLISTIN) </td>
<td class="formItem">COLISTIN</td>
<td class="formItem">3 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>NEOMYCIN SULFATE</strong> (NEOMYCIN) </td>
<td class="formItem">NEOMYCIN</td>
<td class="formItem">3.3 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THONZONIUM BROMIDE</strong> (THONZONIUM BROMIDE) </td>
<td class="formItem">THONZONIUM BROMIDE</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYDROCORTISONE ACETATE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM ACETATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-0564-0</td>
<td class="formItem">10 mL in 1 BOTTLE, DROPPER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050356</td>
<td class="formItem">05/07/2007</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>798c6ae0-0d1b-49ee-a9dd-8b652c5e031d</div>
<div>Set id: 0869fd8d-6dd7-4dc2-b33c-20d72dc47718</div>
<div>Version: 1</div>
<div>Effective Time: 20100129</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
